Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 1/20 | 0.33 |
| ▸ | CCR2 | P41597 | 2/20 | 0.31 |
| ▸ | BCL6 | P41182 | 1/20 | 0.31 |
| ▸ | FLT1 | P17948 | 2/20 | 0.31 |
| ▸ | KDR | P35968 | 2/20 | 0.31 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.31 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.31 |
| ▸ | WDR5 | P61964 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2511459 | 0.92 | PIK3CG (0.35) | IDH1BCL6ADRA2AWDR5KMT2A | |
| SCHEMBL2510495 | 0.87 | PIK3CG (0.36) | WDR5KMT2A | |
| SCHEMBL2511462 | 0.87 | CRBN (0.36) | IDH1CCR2BCL6WDR5KMT2A | |
| SCHEMBL2510811 | 0.83 | PIK3CG (0.37) | WDR5KMT2A | |
| SCHEMBL2511074 | 0.81 | PARP1 (0.32) | — | |
| SCHEMBL2511909 | 0.81 | ALDH1A1 (0.40) | — | |
| SCHEMBL2508796 | 0.80 | PIK3CG (0.45) | WDR5KMT2A | |
| SCHEMBL2510563 | 0.76 | IDH1 (0.38) | IDH1CCR2BCL6LIPG | |
| SCHEMBL2509719 | 0.75 | IDH1 (0.36) | IDH1KDRWDR5KMT2A | |
| SCHEMBL2511407 | 0.73 | HDAC6 (0.41) | IDH1CCR2BCL6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8664214-B2 | Small molecule potentiators of metabotropic glutamate receptors I | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-03-04 | — | — | US | claimed |
| US-8664214-B2 | Small molecule potentiators of metabotropic glutamate receptors I | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-03-04 | — | — | US | disclosed |
| US-20110245232-A1 | NOVEL SMALL MOLECULE POTENTIATORS OF METABOTROPIC GLUTAMATE RECEPTORS I | ABBOTT GMBH & CO. KG (DE) | 2011-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245232-A1 | NOVEL SMALL MOLECULE POTENTIATORS OF METABOTROPIC GLUTAMATE RECEPTORS I | GRM3, GRIN2C, GRIN2B | IDH1 1460/4885CCR2 221/4885BCL6 3045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.